Caliway Biopharmaceuticals C, TW0006919004

Caliway reports 69.60 percent fat reduction: what it means for Caliway Biopharmaceuticals stock

Published on 10/21/2026 at 09:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway Biopharmaceuticals stock was last at TWD 76.00 on October 21, 2026. First-half revenue fell to TWD 3.568 million.

Clinical data and financial scale

On October 2, 2026, CBL-514 helped 69.60 percent of treated participants reduce subcutaneous fat by at least 150 mL.
First-half 2026 revenue was TWD 3.568 million versus TWD 12.212 million in the prior-year period.
Caliway Biopharmaceuticals stock was last at TWD 76.00 on October 21, 2026, with a TWD 118.3 billion market capitalization.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals (ISIN TW0006919004) reported that 69.60 percent of participants receiving CBL-514 reduced subcutaneous fat by at least 150 mL in phase 2 data dated October 2, 2026. The finding supports the company's development program as its lead drug advances through phase 3, according to Caliway Biopharmaceuticals.

What does the data mean for development?

The October 2, 2026 release described a phase 2 result against a 0 percent placebo response for the same 150 mL threshold. It also reported that average visceral fat volume fell 12.01 percent from baseline after four weeks, while the placebo group increased 5.68 percent. Those figures are early clinical evidence, not approval or commercial revenue.

Financially, the company remains in investment mode. First-half 2026 revenue was TWD 3.568 million, down from TWD 12.212 million in the prior-year period, while the first-half net loss narrowed to TWD 330.270 million from TWD 424.378 million, according to Quartr. The comparison matters because development spending remains high while product revenue is still limited.

Three milestones define the program

On September 21, 2026, Caliway reported a phase 2 mean pain-score reduction of 3.1 points versus 1.9 points for placebo in Dercum's disease, as stated by Caliway Biopharmaceuticals. On September 23, 2026, the company dosed the first participant in SUPREME-01, a global phase 3 trial designed to enroll approximately 320 participants, according to Caliway Biopharmaceuticals.

On October 2, 2026, the company presented the 69.60 percent subcutaneous-fat response figure, making the phase 2-to-phase 3 transition the central development milestone.

Upcoming reporting date

The next reporting date is November 11, 2026, according to Investing.com.

Stock valuation reflects clinical risk

Caliway was last quoted at TWD 76.00 on the Taiwan Stock Exchange on October 21, 2026 at 1:30 p.m. TST. Its market capitalization was TWD 118.3 billion, and the 52-week range was TWD 74.80 to TWD 188.00. The wide range places the clinical milestones alongside substantial market volatility.